Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cheaper pill may work as well as costly shot for IVF success in endometriosis patients

NCT ID NCT07134920

Disease control Sponsor: Inception Fertility Research Institute, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 99 IVF patients with endometriosis (a condition where uterine-like tissue grows elsewhere) and a positive BCL6 test. It compared a cheap oral pill (norethindrone acetate) to an expensive injection (Depo Lupron) given before embryo transfer. The goal was to see if the pill works just as well for pregnancy and live birth rates, with fewer side effects and lower cost.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

99 people

The number who actually took part.

Started

Aug 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with a ReceptivaDx BCL6-positive test who completed hormonal suppression therapy prior to embryo transfer cycle

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of recurrent pregnancy loss, recurrent implantation failure, unexplained infertility or severe dysmenorrhea and a positive BCL6 test Receptivadx * Underwent assisted reproductive technology (ART or IVF) * Treated with norethinedrone acetate 5 mg daily for 6 and 8 weeks or two monthly injections of Depo Leuprolide Acetate 7.5mg rior to embryo transfer cycle * Euploid embryo transfer cycle was initiated within 1 week of completion of suppression protocol * Adequate clinical documentation available, including treatment protocol, BCL6 results, and pregnancy outcomes * If Endometrial Receptivity Analysis (ERA) was performed, result must be "receptive" * A minimum uterine lining of 7.5mm was documented by ultrasound prior to the initiation of progesterone Exclusion Criteria: * Use of both norethinedrone acetate and Depo Leuprolide Acetate in the same treatment cycle * Incomplete ART or outcome data * Gestational carrier or egg donor * No prescribed adjuvant therapy (e.g., Lovenox, Neupogen, IVIG)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometriosis female infertility infertility disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infertility (ivf patients) Infertility, female

Contacts and locations

Locations

  • Main Line Fertility

    Bryn Mawr, Pennsylvania, 19010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.